Mumbai based Glenmark Pharmaceuticals inflammatory disorder treatment drug Revamilast will enter the 3rd phase of clinical trial inUSA,UK andIndia very soon. The drug is targeted for the relief of disorders like asthma and rheumatoid arthritis. The molecule had successfully completed its pre clinical and phase I trials that had been conducted inBritain and is expecting Phase-IIb data in rheumatoid arthritis by March 2013 and clinical trial data for asthma by the middle of 2013.
Glenmark also plans to file an Investigational New Drug application (IND) for Revamilast in USA within the 3rd quarter of FY 2012. Glenmark has invested a huge amount in R&D in the recent past for development of innovative and effective drugs.
Source: Business Standard